<DOC>
	<DOCNO>NCT03096275</DOCNO>
	<brief_summary>Takayasu 's arteritis ( TAK ) rare systemic vasculitis cause ischemia inflammation involve organ increase overall mortality rate.The traditional treatment TAK primarily empirical . The commonly use drug treat active TAK glucocorticosteroids ( GC ) immunosuppressant . However , genital toxicity CYC limit long term use . In pilot study carry principal investigator study show mycophenolate mofetil ( MMF ) combine MTX effective adverse effect . The purpose prospective open-label study compare efficacy safety GC+MMF+MTX GC+CYC follow GC+AZA treatment active TAK . 150 patient active TAK recruit randomize 2:1 ratio GC+MMF+MTX group C+CYC AZA group . Patients follow 52 week efficacy safety assessment .</brief_summary>
	<brief_title>Comparison Mycophenolate Mofetil Cyclophosphamide Active Takayasu 's Arteritis</brief_title>
	<detailed_description>Takayasu 's arteritis ( TAK ) rare systemic vasculitis mainly involve aorta major branch . However , prevalent country area along silk road.Young woman child-bearing age prevalent population.It cause ischemia inflammation involve organ increase overall mortality rate.Although may lethal patient , well study due rareness disease.The traditional treatment TAK primarily empirical . The commonly use drug treat active TAK glucocorticosteroids ( GC ) immunosuppressant include cyclophosphamide ( CYC ) , methotrexate ( MTX ) azathioprine ( AZA ) etc . However , drug well study . In addition , genital toxicity CYC , first line medication active TAK , become major limitation long term use chronic disease like TAK . Therefore , new immunosuppressant less toxicity , especially much less genital toxicity low malignancy risk essentially necessary . In pilot study carry principal investigator study show mycophenolate mofetil ( MMF ) combine MTX effective adverse effect . The purpose prospective open-label study compare efficacy safety GC+MMF+MTX GC+CYC follow GC+AZA treatment active TAK . 150 patient active TAK recruit randomize 2:1 ratio GC+MMF+MTX group C+CYC AZA group . Patients follow 52 week assess efficacy safety .</detailed_description>
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Takayasu Arteritis</mesh_term>
	<mesh_term>Aortic Arch Syndromes</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>1 . Patients older 18 yearsold either sex 2 . Patients sign informed consent 3 . Fulfill 1990 ACR Classification Criteria TAK 4 . Patients active disease accord GACTA criterion 1 . Prior adverse event treat MTX result dose reduction discontinuation ; 2 . Prior treatment MMF fail response MMF ; 3 . Prior treatment CYC fail response CYC ; 4 . Renal dysfunction , define estimate GFR &lt; 80 % serum creatinine level high 1.5 time upper normal limit ; 5 . Severe liver function damage define serum ALT AST high 2 time upper normal limit ; 6 . Uncontrolled diabetes melitus ; 7 . Uncontrolled heart failure baseline ; 8 . Active infection include tuberculosis , hepatitis B virus , hepatitis C virus , HIV bacterial fungal infection ; 9 . Active upper GI bleeding past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>cyclophosphamide</keyword>
</DOC>